门静脉系统血栓的抗凝药物选择

张裕; 刘福全

doi:10.3969/j.issn.1001-5256.2018.10.002

门静脉系统血栓的抗凝药物选择

DOI: 10.3969/j.issn.1001-5256.2018.10.002

张裕,
刘福全

首都医科大学附属北京世纪坛医院介入科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2150
- HTML全文浏览量: 14
- PDF下载量: 543
- 被引次数: 0
出版历程
- 出版日期: 2018-10-20

Treatment of portal vein thrombosis: Selection of anticoagulants

Department of Interventional Radiology, Beijing Shijitan Hospital, Capital Medical University

摘要

摘要: 门静脉系统血栓(PVT)已成为常见的疾病,随着数字影像的发展,PVT的检出率明显提高。PVT治疗是以抗凝药物治疗为基础,包括介入治疗、手术治疗等治疗方法的综合治疗。针对抗凝药物治疗PVT的最新观点进行了探讨,提出应根据患者的综合情况选择合适的抗凝治疗方案。
- 静脉血栓形成 /
- 门静脉 /
- 抗凝药 /
- 治疗
Abstract: Portal vein thrombosis ( PVT) has become a common disease in clinical practice, and with the development of digital imaging, the detection rate of PVT has been increased significantly. PVT treatment is a multimodality therapy based on anticoagulant therapy and includes interventional treatment and surgical treatment. This article discusses the latest viewpoints of anticoagulant therapy for PVT and points out that the regimen of anticoagulant therapy should be selected based on patient's conditions.
- venous thrombosis /
- portal veini /
- anticoagulants /
- therapy

HTML全文

参考文献(40)

[1]KOJIMA S, WATANABE N.Current status of portal vein thrombosis in Japan:Results of a questionnaire survey by the Japan Society for Portal Hypertension[J].Hepatol Res, 2018, 48 (4) :244-254.

[2] CHAWLA Y, DUSEJA A, DHIMAN RK.Review article:The modern management of portal vein thrombosis[J].Aliment Pharmacol Ther, 2009, 30 (9) :881-894.

[3] HALL TC, GARCEA G, METCALFE M, et al.Management of acute non-cirrhotic and non-malignant portal vein thrombosis:Asystematic review[J].World J Surg, 2011, 35 (11) :2510-2520.

[4]DAVIES M, SATYADAS T, AKLE CA.Spontaneous resolution of a superior mesenteric vein thrombosis after laparoscopic nissen fundoplication[J].Ann R Coll Surg Engl, 2002, 84 (3) :177-180.

[5]LOFFREDO L, PASTORI D, FARCOMENI A, et al.Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis:Asystematic review and meta-analysis[J].Gastroenterology, 2017, 153 (2) :480-487.e481.

[6]AGENO W, GALLI M, SQUIZZATO A, et al.Is there a role for timely diagnosis and early anticoagulant treatment of portal vein thrombosis in patients with liver cirrhosis?[J].Intern Emerg Med, 2008, 3 (3) :195-196.

[7]PONZIANI FR, ZOCCO MA, TORTORA A, et al.Anticoagulants in cirrhotic patients:Controversies and certainties in PVT management[J].Cardiovasc Hematol Agents Med Chem, 2011, 9 (3) :183-189.

[8]KAWADA PS, BRUCE A, MASSICOTTE P, et al.Coagulopathy in children with liver disease[J].J Pediatr Gastroenterol Nutr, 2017, 65 (6) :603-607.

[9]AMITRANO L, GUARDASCIONE MA, MENCHISE A, et al.Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis[J].J Clin Gastroenterol, 2010, 44 (6) :448-451.

[10]SENZOLO MT, M SARTORI T, ROSSETTO V, et al.Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis[J].Liver Int, 2012, 32 (6) :919-927.

[11] VILLA E, CAMMA C, MARIETTA M, et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J].Gastroenterology, 2012, 143 (5) :1253-1260.e1254.

[12]DELGADO MG, SEIJO S, YEPES I, et al.Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis[J].Clin Gastroenterol Hepatol, 2012, 10 (7) :776-783.

[13]NORTHUP PG, SUNDARAM V, FALLON MB, et al.Hypercoagulation and thrombophilia in liver disease[J].J Thromb Haemost, 2008, 6 (1) :2-9.

[14]HAAS S.The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes[J].Semin Vasc Med, 2003, 3 (2) :139-146.

[15]HIRSH J, WARKENTIN TE, SHAUGHNESSY SG, et al.Heparin and low-molecular-weight heparin:Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety[J].Chest, 2001, 119 (1 Suppl) :64s-94s.

[16]BIANCHINI M, CAVANI G, BONACCORSO A, et al.Low molecular weight heparin does not increase bleeding and mortality postendoscopic variceal band ligation in cirrhotic patients[J].Liver Int, 2018, 38 (7) :1253-1262.

[17]KWON J, KOH Y, YU SJ, et al.Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis:Efficacy and the risk of hemorrhagic complications[J].Thromb Res, 2018, 163:71-76.

[18]YANG H, KIM SR, SONG MJ.Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban[J].Clin Mol Hepatol, 2016, 22 (4) :499-502.

[19]HUGENHOLTZ GC, NORTHUP PG, PORTE RJ, et al.Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?[J].Blood Rev, 2015, 29 (2) :127-136.

[20]CHEN H, LIU L, QI X, et al.Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis[J].Eur J Gastroenterol Hepatol, 2016, 28 (1) :82-89.

[21]HANAFY AS, ABD-ELSALAM S, DAWOUD MM.Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis[J].Vascul Pharmacol, 2018.[Epub ahead of print]

[22]PANNACH S, BABATZ J, BEYER-WESTENDORF J.Successful treatment of acute portal vein thrombosis with rivaroxaban[J].Thromb Haemost, 2013, 110 (4) :626.

[23]LENZ K, DIEPLINGER B, BUDER R, et al.Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban[J].Z Gastroenterol, 2014, 52 (10) :1175-1177.

[24]INTAGLIATA NM, HENRY ZH, MAITLAND H, et al.Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation[J].Dig Dis Sci, 2016, 61 (6) :1721-1727.

[25]DARIUSHNIA SR, HASKAL ZJ, MIDIA M, et al.Quality improvement guidelines for transjugular intrahepatic portosystemic shunts[J].J Vasc Interv Radiol, 2016, 27 (1) :1-7.

[26]KEARON C, AKI EA, ORNELAS J, et al.Antithrombotic therapy for VTE disease:CHEST guideline and expert panel report[J].Chest, 2016, 149 (2) :315-352.

[27]BASIT SA, STONE CD, GISH R.Portal vein thrombosis[J].Clin Liver Dis, 2015, 19 (1) :199-221.

[28]PLESSIER A, RAUTOU PE, VALLA DC.Management of hepatic vascular diseases[J].J Hepatol, 2012, 56 (Suppl 1) :s25-s38.

[29] HOEKSTRA J, JANSSEN HL.Vascular liver disorders (II) :portal vein thrombosis[J].Neth J Med, 2009, 67 (2) :46-53.

[30]TURNES J, GARCIA-PAGAN JC, GONZALEZ M, et al.Portal hypertension-related complications after acute portal vein thrombosis:Impact of early anticoagulation[J].Clin Gastroenterol Hepatol, 2008, 6 (12) :1412-1417.

[31]WEBSTER GJ, BURROUGHS AK, RIORDAN SM.Review article:portal vein thrombosis-new insights into aetiology and management[J].Aliment Pharmacol Ther, 2005, 21 (1) :1-9.

[32]OGREN M, BERGQVIST D, BJORCK M, et al.Portal vein thrombosis:Prevalence, patient characteristics and lifetime risk:A population study based on 23, 796 consecutive autopsies[J].World JGastroenterol, 2006, 12 (13) :2115-2119.

[33]DELEVE LD, VALLA DC, GARCIA-TSAO G, et al.Vascular disorders of the liver.[J].Hepatology, 2009, 49 (5) :1729-1764.

[34]VILLA E, CAMMC, MARIETTA M, et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J].Gastroenterology, 2012, 143 (5) :1253-1260.

[35]CUI SB, SHU RH, YAN SP, et al.Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B[J].Eur J Gastroenterol Hepatol, 2015, 27 (8) :914-919.

[36]RODRGUEZ-LEAL GA, MORN S, CORONA-CEDILLO R, et al.Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient[J].World J Hepatol, 2014, 6 (7) :532-537.

[37]LI MX, ZHANG XF, LIU ZW, et al.Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis[J].Hepatobiliary Pancreat Dis Int, 2013, 12 (5) :512-519.

[38]RODRIGUEZ-CASTRO KI, SIMIONI P, BURRA P, et al.Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis[J].Liver Int, 2012, 32 (10) :1465-1476.

[39]PELLICELLI AM, GUARASCIO P, D'AMBROSIO C, et al.186 portal vein thrombosis in cirrhotic patients:Safety and efficacy of low dosage of enoxaparin[J].J Hepatol, 2010, 52 (1) :s80.

[40]LISMAN T, KAMPHUISEN PW, NORTHUP PG, et al.Established and new-generation antithrombotic drugs in patients with cirrhosis-possibilities and caveats[J].J Hepatol, 2013, 59 (2) :358-366.

施引文献

资源附件(0)

访问统计